References
- Saba G, Mékaoui L, Leboyer M, et al. Patients’ health literacy in psychotic disorders. Neuropsychiatr Dis Treatment. 2007;3:511.
- Keshavan MS, Giedd J, Lau JY, et al. Changes in the adolescent brain and the pathophysiology of psychotic disorders. Lancet Psychiatry. 2014;1:549–558.
- Vancampfort D, Stubbs B, Mitchell AJ, et al. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta‐analysis. World Psychiatry. 2015;14:339–347.
- Almeida H, Lobão P, Frigerio C, et al. Preparation, characterization and biocompatibility studies of thermoresponsive eyedrops based on the combination of nanostructured lipid carriers (NLC) and the polymer Pluronic F-127 for controlled delivery of ibuprofen. Pharm Dev Technol. 2017;22:336–349.
- Canitano R, Scandurra V. Risperidone in the treatment of behavioral disorders associated with autism in children and adolescents. Neuropsychiatr Dis Treatment. 2008;4:723–730.
- Khames A. Investigation of the effect of solubility increase at the main absorption site on bioavailability of BCS class II drug (risperidone) using liquisolid technique. Drug Deliv. 2017;24:328–338.
- Rahman Z, Zidan AS, Khan MA. Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. Int J Pharm. 2010;400:49–58.
- Bandi S, Sanka K, Bakshi V. Enhanced oral delivery of risperidone through a novel self-nanoemulsifying powder (SNEP) formulations: in-vitro and ex-vivo assessment. J Microencapsul. 2016;33:544–553.
- Shakeel F, Alanazi FK, Alsarra IA, et al. Solubility of antipsychotic drug risperidone in Transcutol + water co-solvent mixtures at 298.15 to 333.15 K. J Mol Liq. 2014;191:68–72.
- Center for drug evaluation and research. Approval package for Risperdal; [cited 2017 May 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/020272 Orig1s036,s041,020588Orig1s024,s028,s029,21444Orig1s008,s015.pdf
- Tanneberger K, Rico-Rico A, Kramer NI, et al. Effects of solvents and dosing procedure on chemical toxicity in cell-based in vitro assays. Environ Sci Technol. 2010;44: 4775–4781.
- Tadros TF. Surfactants in pharmaceutical formulations. Appl Surf: Principles Appl. 2005;433–501.
- Salem H, Kharshoum RM. Nanoprecipitation technique for preparation of sterically stabilized risperidone nanosuspension: in vitro and in vivo study. Int J Pharm Pharm Sci. 2016;8:136–142.
- Rabinow BE. Nanosuspensions in drug delivery. Nat Rev Drug Discov. 2004;3:785–796.
- Lu Y, Qi J, Dong X, et al. The in vivo fate of nanocrystals. Drug Discov Today. 2017;22:744–750.
- Zhou Y, Du J, Wang L, et al. Nanocrystals technology for improving bioavailability of poorly soluble drugs: a mini-review. J Nanosci Nanotechnol. 2017;17:18–28.
- Thakkar S, Shah V, Misra M, et al. Nanocrystal based drug delivery system: conventional and current scenario. Recent Patents Nanotechnol. 2017;11:130–145.
- Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 2010;390: 242–249.
- Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. ISRN Pharm. 2012;2012:1–10.
- Imaizumi H, Nambu N, Nagai T. Stability and several physical properties of amorphous and crystalline forms of indomethacin. Chem Pharm Bull. 1980;28:2565–2569.
- Van Eerdenbrugh B, Van den Mooter G, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364:64–75.
- Malamatari M, Somavarapu S, Taylor KM, et al. Solidification of nanosuspensions for the production of solid oral dosage forms and inhalable dry powders. Expert Opin Drug Deliv. 2016;13:435–450.
- Bruni G, Amici L, Berbenni V, et al. Drug-excipient compatibility studies. Search of interaction indicators. J Therm Anal Calorim. 2002;68:561–573.
- Joshi B, Patil V, Pokharkar V. Compatibility studies between carbamazepine and tablet excipients using thermal and non-thermal methods. Drug Dev Ind Pharm. 2002;28: 687–694.
- Taneja S, Shilpi S, Khatri K. Formulation and optimization of efavirenz nanosuspensions using the precipitation-ultrasonication technique for solubility enhancement. Artif Cells Nanomed Biotechnol. 2016;44:978–984.
- Van Eerdenbrugh B, Froyen L, Van Humbeeck J, et al. Alternative matrix formers for nanosuspension solidification: dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. Eur J Pharm Sci. 2008;35:344–353.
- Wang Y, Zheng Y, Zhang L, et al. Stability of nanosuspensions in drug delivery. J Control Release. 2013;172: 1126–1141.
- Thakkar S, Sharma D, Misra M. Comparative evaluation of electrospraying and lyophilization techniques on solid state properties of erlotinib nanocrystals: assessment of in-vitro cytotoxicity. Eur J Pharm Sci. 2017;111:257–269.
- [cited 2017 Jun 16]. Available from: http://www.separatedbyexperience.com/news/attachments/ANCCSRESSOLV_1010- Residual_Solvents.pdf
- Navitha A, Jogala S, Krishnamohan C, et al. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. J Adv Pharm Technol Res. 2014;5:84.
- Silva A, González-Mira E, García M, et al. Preparation, characterization and biocompatibility studies on risperidone-loaded solid lipid nanoparticles (SLN): high pressure homogenization versus ultrasound. Colloids Surf B Biointerfaces. 2011;86:158–165.
- Sinha B, Müller RH, Möschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453:126–141.
- [cited 2017 May 20]. Available from: https://www.organicdivision.org/orig/organic_solvents.html
- Lu Y, Wang Z-h, Li T, et al. Development and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation. J Control Release. 2014;176:76–85.
- Verma S, Kumar S, Gokhale R, et al. Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening. Int J Pharm. 2011;406:145–152.
- Tso C-P, Zhung C-M, Shih Y-H, et al. Stability of metal oxide nanoparticles in aqueous solutions. Water Sci Technol. 2010;61:127–133.
- Date PV, Samad A, Devarajan PV. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech. 2010;11:304–313.
- Saez A, Guzman M, Molpeceres J, et al. Freeze-drying of polycaprolactone and poly(d,l-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs. Eur J Pharm Biopharm. 2000;50:379–387.
- Basic Principles of freeze drying. SP Scientific [cited 2017 Dec 12]. Available from: https://www.spscientific.com/freeze-drying-lyophilization-basics/
- Dynamic light scattering general term defined. Malvern [cited 2017 Dec 15]. Available from: http://www.biophysics.bioc.cam.ac.uk/wp-content/uploads/2011/02/DLS_Terms_defined_Malvern.pdf
- Sis H, Birinci M. Effect of nonionic and ionic surfactants on zeta potential and dispersion properties of carbon black powders. Colloids Surf A: Physicochem Eng Aspects. 2009;341:60–67.
- Gao B, Wang J, Wang D, et al. A novel preparation method for drug nanocrystals and characterization by ultrasonic spray-assisted electrostatic adsorption. Int J Nanomed. 2013;8:3927.
- Barnaba K, Dov D, Ben-Zion D, et al., inventors. Preparation of risperidone. United States; 2004.
- Cheow WS, Kiew TY, Yang Y, et al. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles. Mol Pharm. 2014;11: 1611–1620.
- Wlodarski K, Sawicki W, Paluch K, et al. The influence of amorphization methods on the apparent solubility and dissolution rate of tadalafil. Eur J Pharm Sci. 2014;62:132–140.
- Basic Principles of freeze drying. SP Scientific [cited 2017 Jun 16]. Available from: http://www.spscientific.com/freeze-drying-lyophilization-basics/
- [cited 2017 Jun 16]. [Internet]. Available from: https://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3 &cad=rja&uact=8&ved=0ahUKEwiKhKyju8HUAhXEq48KHQ IHDFYQFgg9MAI&url=http%3A%2F%2Fhrcak.srce.hr%2Ffile %2F150447&usg=AFQjCNGYCkCumIEAzbs6TCNi8W xbUuzyyg
- Thanh NT, Maclean N, Mahiddine S. Mechanisms of nucleation and growth of nanoparticles in solution. Chem Rev. 2014;114:7610–7630.
- Klick S, Sköld A. Validation of a generic analytical procedure for determination of residual solvents in drug substances. J Pharm Biomed Anal. 2004;36:401–409.